Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2019

View Archived Issues

GSK-2702926A ameliorates a range of FXS-associated deficits in vivo

RNA circles the wagons in aggressive cancer

Simpler recipe for astrocyte-neuron conversion

Sangamo Therapeutics presents data from phase I/II EMPOWERS study of SB-318

FDA clears IND application for first-in-human study of PRGN-3005

M2SR shows protection against a highly mismatched influenza virus in phase II human challenge study

Preliminary data presented from a subgroup of patients in phase IIb study of NPS plus trastuzumab

Nitto BioPharma initiates phase I study of NBF-006

Enrollment ongoing in phase I study of CRV-101 vaccine candidate

Regimen delays neuroblastoma progression, prolongs survival

Pharmazz presents preliminary phase II data for PMZ-1620 in patients with cerebral ischemic stroke

Using ICAS to develop novel mouse model of moyamoya syndrome

Plasma BACE1 protein as a new biomarker for the diagnosis of cerebral amyloid angiopathy

Clinical and nonclinical data support entry of rodatristat into phase II this year

Targeting PKM improves outcome after ischemic stroke

New Bruton tyrosine kinase inhibitors discovered at Bristol-Myers Squibb

Isocure Biosciences patents mutant isocitrate dehydrogenase inhibitors

IFM Tre identifies new NLRP3 inflammasome inhibitors

Nanjing Sanhome Pharmaceutical synthsizes acetyl-CoA carboxylase inhibitors

Gyeonggido Business & Science Accelerator, Korpharm disclose benzylidene acetone derivatives

Jubilant enters drug discovery collaboration with Sanofi for neurological disorders

BioArctic's evaluation of SC-0806 for complete spinal cord injury progresses into phase II

ProMIS Neurosciences identifies MAbs targeting alpha-synuclein

Reproducible murine model of intracranial aneurysm developed

Zymeworks initiates phase I study of ZW-49 in HER2-positive cancers

Phase I interim data show mRNA-1653 boosts serum neutralization titers against hMPV and PIV3

Summit begins phase III trials of ridinilazole for C. difficile infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...